<DOC>
	<DOCNO>NCT01070862</DOCNO>
	<brief_summary>The aim study evaluate efficacy tolerability Thalidomide first-line treatment multiple myeloma induction treatment young patient , Dexamethasone autotransplant , elderly patient combination conventional chemotherapy consolidation/maintenance therapy young elderly patient plateau-phase .</brief_summary>
	<brief_title>Multiple Myeloma Treated With Thalidomide Before Autotransplant With Conventional Chemotherapy Consolidation/Maintenance Treatment Young Elderly Patients : 3 Randomized Studies .</brief_title>
	<detailed_description>MY-TAG : Thalidomide induction treatment high dose therapy , young patient MY-DECT : Thalidomide induction treatment conventional chemotherapy , elderly patient MY-PLAT : Thalidomide Dexamethasone plateau-phase , high dose therapy conventional chemotherapy</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>MYTAG ( autotransplant ) : age 1865 , multiple myeloma SalmonDurie stage II , stage III symptomatic stage I ( lytic bone lesion 25 % increase monoclonal protein ) MYDECT ( conventional chemotherapy ) : qge 6680 , multiple myeloma SalmonDurie stage II , stage III symptomatic stage I ( lytic bone lesion 25 % increase monoclonal protein ) MYPLAT ( maintenance plateauphase ) : patient treat MYTAG MYDECt least minimal response ( 25 % decrease M protein ) 36 month autotransplant last chemotherapy MYTAG : age 66 , smolder stage I multiple myeloma , previous therapy , plasma cell leukemia , creatinine &gt; 300 micromol/L , liver failure , anthracycline contraindicate , thalidomide contraindicate , corticosteroid contraindicate MYDECT : age &lt; 66 &gt; 80 , smolder stage I multiple myeloma , previous therapy , plasma cell leukemia , creatinine &gt; 300 micromol/L , liver failure , thalidomide contraindicate , corticosteroid contraindicate MYPLAT : response progressive disease , randomization &gt; 6 since autotransplant last chemotherapy , creatinine &gt; 300 micromol/L , liver failure , thalidomide contraindicate , corticosteroid contraindicate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>multiple myeloma , treatment , first line</keyword>
</DOC>